Impact of Mutations at Residue I223 of the Neuraminidase Protein on the Resistance Profile, Replication Level, and Virulence of the 2009 Pandemic Influenza Virus

被引:48
作者
Pizzorno, Andres [1 ,2 ]
Abed, Yacine [1 ,2 ]
Bouhy, Xavier [1 ,2 ]
Beaulieu, Edith [3 ]
Mallett, Corey [3 ]
Russell, Rupert [4 ]
Boivin, Guy [1 ,2 ]
机构
[1] CHUQ CHUL, Res Ctr Infect Dis, Quebec City, PQ, Canada
[2] Univ Laval, Quebec City, PQ, Canada
[3] GlaxoSmithKline Biol, Laval, PQ, Canada
[4] Univ St Andrews, St Andrews, Fife, Scotland
基金
加拿大健康研究院;
关键词
A H1N1 VIRUS; INHIBITOR RESISTANCE; IN-VITRO; OSELTAMIVIR; TRANSMISSION; PERAMIVIR; FERRETS; CHILD; PROPHYLAXIS; EMERGENCE;
D O I
10.1128/AAC.05994-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Amino acid substitutions at residue I223 of the neuraminidase (NA) protein have been identified in 2009 pandemic influenza (pH1N1) variants with altered susceptibilities to NA inhibitors (NAIs). We used reverse genetics and site-directed mutagenesis to generate the recombinant A/Quebec/144147/09 pH1N1 wild-type virus (WT) and five (I223R, I223V, H275Y, I223V-H275Y, and I223R-H275Y) NA mutants. A fluorimetry-based assay was used to determine 50% inhibitory concentrations (IC(50)s) of oseltamivir, zanamivir, and peramivir. Replicative capacity was analyzed by viral yield assays in ST6GalI-MDCK cells. Infectivity and transmission of the WT, H275Y, and I223V-H275Y recombinant viruses were evaluated in ferrets. As expected, the H275Y mutation conferred resistance to oseltamivir (982-fold) and peramivir (661-fold) compared to the drug-susceptible recombinant WT. The single I223R mutant was associated with reduced susceptibility to oseltamivir (53-fold), zanamivir (7-fold) and peramivir (10-fold), whereas the I223V virus had reduced susceptibility to oseltamivir (6-fold) only. Interestingly, enhanced levels of resistance to oseltamivir and peramivir and reduced susceptibility to zanamivir (1,647-, 17,347-, and 16-fold increases in IC(50)s, respectively) were observed for the I223R-H275Y recombinant, while the I223V-H275Y mutant exhibited 1,733-, 2,707-, and 2-fold increases in respective IC(50)s. The I223R and I223V changes were associated with equivalent or higher viral titers in vitro compared to the recombinant WT. Infectivity and transmissibility in ferrets were comparable between the recombinant WT and the H275Y or I223V-H275Y recombinants. In conclusion, amino acid changes at residue I223 may alter the NAI susceptibilities of pH1N1 variants without compromising fitness. Consequently, I223R and I223V mutations, alone or with H275Y, need to be thoroughly monitored.
引用
收藏
页码:1208 / 1214
页数:7
相关论文
共 38 条
  • [1] Abed Y, 2006, ANTIVIR THER, V11, P971
  • [2] Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation
    Abed, Yacine
    Simon, Philippe
    Boivin, Guy
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (07) : 2819 - 2822
  • [3] Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an Immunocompromised child
    Baz, Mariana
    Abed, Yacine
    McDonald, Jane
    Boivin, Guy
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (12) : 1555 - 1561
  • [4] Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis
    Baz, Mariana
    Abed, Yacine
    Papenburg, Jesse
    Bouhy, Xavier
    Hamelin, Marie-Eve
    Boivin, Guy
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (23) : 2296 - 2297
  • [5] BioCryst Pharmaceuticals Inc, 2010, BIOCRYSTS PARTN SHIO
  • [6] The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza
    Birnkrant, Debra
    Cox, Edward
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (23) : 2204 - 2207
  • [7] Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P969
  • [8] SEQUENCE AND STRUCTURE ALIGNMENT OF PARAMYXOVIRUS HEMAGGLUTININ-NEURAMINIDASE WITH INFLUENZA-VIRUS NEURAMINIDASE
    COLMAN, PM
    HOYNE, PA
    LAWRENCE, MC
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (06) : 2972 - 2980
  • [9] Daiichi Sankyo Company Ltd, 2010, DAIICH SANK REC APPR
  • [10] DAVIES BE, 2010, J ANTIMICROB CHEM S2, V65, P5, DOI DOI 10.1093/JAC/DKQ015